Journal of Oncology Research and Treatment
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Oncol Res Treat, Vol 6(3)
  • DOI: 10.4172/aot.1000162

HIV Infection and Pre-Cancerous Cervical Lesion among Women in Ethiopia: A Systemic Review and Meta-Analysis

Abiyu Ayalew Assefa1*, Kaleab Tesfaye Tegegne1, Eleni Tesfaye Tegegne2, Mekibib Kassa Tessema3, Geleta Abera Gemeda1, Getnet Tafese Walesa4 and Demelash Zeleke Berga5
1Department of Public Health, Hawassa College of Health Science, Hawassa, Ethiopia
2School of Nursing College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia
3Leishmania Research and Treatment Centre, University of Gondar, Gondar, Ethiopia
4Department of Pharmacy, Hawassa College of Health Science, Hawassa, Ethiopia
5Department of Nursing, Hawassa College of Health Science, Hawassa, Ethiopia
*Corresponding Author: Abiyu Ayalew Assefa, Department of Public Health, Hawassa College of Health Science, Hawassa, Ethiopia, Tel: +0924032526, Email: abiyman143@gmail.com

Received: 05-Mar-2021 / Accepted Date: 19-Mar-2021 / Published Date: 26-Mar-2021 DOI: 10.4172/aot.1000162

Abstract

Background: Cervical cancer is the second most prevalent cancer among women in the developing countries including Ethiopia. Precancerous lesions can be developed and risk to the development of cervical cancer over time. Early identification of the precancerous lesion and its risk factor is paramount in preventing cervical cancer.

Objective: The aim of this study was to determine the impact of HIV status on pre-cancerous cervical lesions.

Methods: Searches were carried out in Pub Med, Google Scholar, web of science and Scopus. Studies were selected for meta-analysis if they reported the number of pre-cancerous cervical lesion, according to HIV status. For critical appraisal of studies, Newcastle-Ottawa Quality Assessment Scale (NOS) was used. The analysis was conducted by using meta-essential and Revman software. To test the heterogeneity of studies, the Cochran Q test and I2 test statistics were used. To detect publication bias of the studies, the funnel plot and Egger’s test were used. The pooled prevalence of cervical cancer screening and the odds ratio (OR) with a 95% confidence interval was presented using forest plots.

Results: Overall, 9 of 360 records identified through database searching met inclusion criteria. The pooled adjusted odds ratios for pre-cancerous cervical lesion comparing Women who are HIV positive versus Women who are HIV negative was OR 1.75 (95% CI: 1.40, 2.18), P<0.00001, I2=0%).

Conclusion: These findings support the hypothesis that being HIV positive has a marked effect on PCC L and the risk of PCCL. Government and other stakeholders should give high priority in early screening of cervical cancer for patients living with HIV.s.

Keywords: Cervical cancer; Ethiopia; HIV; Meta-analysis; Precancerous lesions; Systematic review

Introduction

Cervical Cancer (CC) is one of the gravest threats to women’s lives. Precancerous lesions are biologically defined as lesions that can progress potentially to invasive cervical cancer if left untreated [1].

It is estimated that over a million women worldwide currently have cervical cancer [1]. Global cancer statistics indicate that CC ranks fourth for both incidence (6.6%) and mortality (3.5%) among females in 2018 [2]. About 85% of new cases and 87% of all deaths of CC occur in the less developed regions [3]. In Ethiopia, cervical cancer is the second most cause of cancer deaths among women aged 15 to 44 years next to breast cancer [4].

The joint united nations programme on HIV/AIDS (UNAIDS) estimates that 36.9 million [31.1 million-43.9 million] people were HIV positives in 2017 and around 7000 young women aged 15-24 years become infected with HIV Every week [5]. According to Ethiopian Demographic and Health Survey 2016 report HIV/AIDS prevalence among women aged 15 to 49 years was 1.2% [6].

According to a World Health Organization, in areas where HIV is endemic, cervical cancer screening results may be positive for precancerous lesions in 15%-20% of the target population [1]. In women with HIV, a cervical pre-cancer might develop into an invasive cancer faster than it normally would [7]. About 534,000 women over age 15 living with HIV in Ethiopia are among the most vulnerable to cervical cancer since women infected with HIV/AIDS are ten times at higher risk for precancerous lesions [8]. In Ethiopia, few studies have been conducted to assess the predictors of the cervical precancerous lesion. Factors identified by those studies were: being in the older age group, having multiple sexual partners, Age of first intercourse (years), history of STI [9-12].

Precursor stage of cervical cancer lasts many years before becoming invasive cancer but when it became advanced the following symptoms like; abnormal vaginal bleeding, pelvic pain, vaginal discharge and pain during sex will be observed [13].

Conventional (Pap) and Liquid Based Cytology (LBC), HPV (Human Papilloma Virus) testing for high risk HPV types (e.g. types 16 and 18) and Visual inspection with Acetic Acid (via) are commonly used methods for screening; but via followed by treatment is an effective method, relatively simple procedure and feasible in resource limited areas[14]. The 2030 Sustainable Development Goals on noncommunicable diseases (NCD’s) is to reduce by one third premature mortality from NCD’s which extends to cervical cancer, the second most common cause of cancer associated mortality for women [15].

Despite having national cancer control plan to reduce cancer incidence and mortality in Ethiopia by 15% by 2020, Cancer research in Ethiopia is not commensurate with the magnitude of the problem [16]. Studies show inconsistent and inconclusive association between HIV infection and pre-cancerous cervical cancer (PCCL). Therefore, this systematic review and meta-analysis was designed to link the twin burdens of HIV and PCCL by establishing an association between HIV and PCCL in Ethiopia.

Materials and Methods

Study design

This is a systematic review which includes a meta-analysis.

Data sources and search strategy

Review protocol not exist since, we did not register in Cochran’s library. The PRISMA statement for the reporting of systematic reviews recommended by the Cochrane Collaboration was followed while conducting this meta-analysis [Additional file 1] [17]. Observational studies (Case control and cross-sectional studies) on HIV status and PCCL were included in our meta-analysis. Following PRISMA guidelines, Two investigators retrieved studies through internet search from the electronic databases of Pub Med, Google Scholar, web of science and Scopus from Nov. 2-12 2020.

Searches were performed using the search terms under two search themes that were combined using the Boolean operator “AND”. For the theme of “Pre-cancerous cervical lesion” a combination of text words was used: “cervical cancer”, “cervical cancer and HIV status”, “precancerous cervical lesion”, “Visual inspection with acetic acid”, “cervical cancer screening”, “factor of cervical cancer”, pre-cancerous cervical lesion+HIV status Ethiopia For the theme of “HIV status”, “Positive” and “other population group” was used.

Eligibility criteria

Studies were included in the review if; (1) the study was an observational study (cross-sectional study, case-control study, or cohort study), (2) the outcome of interest was PCCL, (3) the study reported the number of pre-cancerous cervical lesion, according to HIV status and (4) Newcastle-Ottawa Scale (NOS) or adapted Newcastle-Ottawa Scale (NOS) score of 5 or greater (5) the studies published from 2015 to 2020.

Studies that not included participants with Pre-cancerous cervical lesion according to HIV status and studies conducted not in Ethiopia were excluded to avoid the combination of studies that were not comparable.

Data extraction and quality assessment

The data extraction and quality assessment was performed by three reviewers that were not involved during internet search from electronic databases to reduce bias. The following information was extracted from each eligible study: first author’s name, study design, source of study population, sample size, number of HIV positive and HIV negative and definition of PCCL.

All studies conducted multivariable analysis. As a result, variables that were fully adjusted for potential confounding were selected.

Quality assessment was conducted using the ten-star Newcastle Ottawa Quality Assessment Scale (NOS) [18]. We have selected studies with greater than 50% NOS score (Table 1).

Study Selection Comparability Outcome NOS scale
Adela.G ***** ** *** 10
Assefa.A ***** ** ** 9
Dekissesa.Z ***** ** * 8
Derbie.A ***** ** ** 9
Geberemariam.A ***** ** *** 10
Kassa.R ***** ** ** 9
Misgna.K ***** ** *** 10
Teka.T ***** ** * 8
Tekalegne.Y ***** ** * 8

Table 1: Newcastle-Ottawa quality assessment scale of included studies in Ethiopia, 2020.

Three authors assessed the articles for inclusion in the review (Figure 1). Disagreements between assessors were managed through discussion and majority decisions among the three reviewers.

advances-oncology-PRISMA

Figure 1: PRISMA flow chart of the included studies selection process.

Outcome measurement

Visual Inspection of the Cervix with Acetic Acid (via): Screening method which involves naked-eye inspection of the uterine cervix 1 min after application of a 3%-5% solution of acetic acid using a cotton swab or a spray [8,19].

PCCL: If a woman with via result of raised and thickened white plaques or acetowhite epithelium, usually near the Squamo-Columnar Junction (SCJ) diagnosed as having PCCL and via result of smooth, pink, uniform and featureless cervix; cervical ectropion; polyp; cervicitis; inflammation; and/or nabothian cyst after applying a dilute solution of acetic acid is considered as not having PCCL [8,19].

Publication bias and heterogeneity

We quantified the existence of heterogeneity with I2 and its corresponding P-value. A value of 25%, 50% and 75% was used to declare the heterogeneity test as low, medium and high respectively [20].

Publication bias was checked subjectively through observing the funnel plot and objectively through Egger’s regression test. Hence, statistical significant publication bias was declared at a p-value less than 0.05 at 95% CI.

Analysis of data

The meta-analysis was conducted using Revman software (version 5.3) and Meta essential software. The relationship between HIV status and PCCL was examined using the number of PCCL in HIV positive versus HIV negative. A meta-analysis comparing PCCL between HIV positive and HIV negative in all included studies was performed.

A fixed-effects model was used to estimate the pooled ORs with 95% CIs because there was no evidence of heterogeneity [21]. Forest plots were used to present the pooled estimate with the 95% Confidence Interval (CI). All statistical tests were two sided and P-value <0.05 was considered statistically significant (Figure 1).

Results

Study searches and selection

In the initial search, we found a total of 360 records from different electronic search databases which include; Pub Med, Google Scholar, web of science and Scopus.

From this, 215 duplicate records were removed and 17 records were excluded after screening by title and abstracts. We assessed the full texts of 13 remaining records for eligibility and 3 records were further excluded by the inclusion and exclusion criteria and 1 excluded by methodological issue. We have selected studies with high NOS score (Table 1). Finally, 9 studies were included for systemic review and meta-analysis [9-12, 22-26] to estimate the pooled adjusted odds ratio of HIV status with pre-cancerous cervical lesion (Figure 1).

Characteristics of the studies

These nine studies were published from 2015 to 2020. All the studies included in this review were observational (case-control, cross sectional) studies. A total of 2949 women were included in the analysis. The included studies reported sample size ranging from 164(10) to 528(25) (Table 2).

Articles Sample size Tittle/study design HIV Status PCCL Ref.
Yes No
Adella. G 407 Predictors of Pre-cancerous cervical lesions Among Women Screened for Cervical Cancer in Bahir Dar Town, Ethiopia: A Case–Control Study Positive 17 44 11
Negative 83 247  
Assefa. A 391 Prevalence and predictors of Pap smear cervical epithelial cell abnormality among HIV-positive and negative women attending gynecological examination in cervical cancer screening center at Debre Marko’s referral hospital, East Gojjam, Northwest Ethiopia: A comparative cross-sectional study Positive 35 162 12
Negative 20 174  
Deksissa. Z 334 Prevalence and factors associated with VIA positive result among clients screened at Family Guidance Association of Ethiopia, south west area office, Jimma model clinic, Jimma, Ethiopia 2013: a cross-sectional study Positive 21 113 22
Negative 20 148  
Derbie. A 428 Cervical lesion detection using visual inspection with acetic Acid and associated factors among Ethiopian women: A facility-based cross-sectional study Positive 33 161 26
Negative 14 107  
Gebremariam. A 343 Factors associated with cervical precancerous lesions among women screened for cervical cancer in Addis Ababa, Ethiopia: A case control study Positive 46 53 9
Negative 67 173  
Kassa. R 164 Risk factors associated with precancerous cervical lesion among women screened at Marie Stops Ethiopia, Adama town, Ethiopia 2017: a
case control study
Positive 9 9 10
Negative 33 74  
Misgina. K 342 Prevalence of pre-cancerous cervical lesion and associated factors among women in North Ethiopia: An institution-based cross-sectional study Positive 1 15 23
Negative 22 304  
Teka. T 528 Magnitude and Factors Associated with Precervical Cancer among Screened Women in Southern Ethiopia: A facility based cross-sectional study Positive 17 21 25
Negative 129 361  
Tekalegn. Y 222 Determinants of VIA Positivity Among Women Screened for Cervical Precancerous Lesion in Public Hospitals of Oromia Region, Ethiopia: Unmatched Case-Control Study Positive 26 35 24
Negative 45 110  

Table 2: Characteristics of studies for HIV infection and pre-cancerous cervical lesion among women in Ethiopia, 2020(n=9).

Of 818(27.7%) HIV positive study participants, 205(25.1%) of them had pre-cancerous cervical lesion. Among 2131(72.3%) HIV negative participants, 433(20.3%) of them have pre-cancerous cervical lesion.

The overall proportion of PCCL was 6.95% and 14.68% among HIV positive and HIV negative respectively (Table 2).

The association between HIV status and pre-cancerous cervical lesion

The pooled adjusted odds ratios for pre-cancerous cervical lesion comparing Women who are HIV positive versus Women who are HIV negative was OR 1.75(95% CI: 1.40, 2.18), P<0.00001, I2=0%). There was no significant heterogeneity among the 9 studies (Chi²=4.66, DF=8 I²=0% and P=0.793) (Figure 2).

advances-oncology-cervical

Figure 2: Forest plot for the effect of HIV infection on pre-cancerous cervical lesion among women in Ethiopia, 2020.

We assessed the funnel plot for asymmetry by visual inspection for pre-cancerous cervical lesion and HIV status. No publication bias was observed (Egger’s test: P=0.455, Begg’s test: P=0.532).

Discussion

This meta-analysis determined the association between HIV status and pre-cancerous cervical lesions among woman in Ethiopia using nine studies. This study revealed that 628(21.6%) of the women were positive for pre-cancerous cervical lesion.

According to the results of this meta-analysis, the pooled adjusted odds ratios for all studies revealed that, odds of PCCL in Ethiopia among HIV positive woman is 1.75 times more likely compared with HIV negative (OR 1.75; 95%CI: 1.40, 2.18, P<10-6, I2=0%)

This finding is consistent with several studies conducted in Tanzania [27,28], Swaziland [29], Zimbabwe [30], South Africa [31], Dessie [32] and Yirgalem [33] which show association of HIV and precancerous cervical lesions. The finding of this study is also supported by other studies in Kenya [34] and Senegal [35] which are reporting an increased risk of cervical dysplasia among HIV positive compared to HIV negative women. This could be due to the role of HIV infection on immune system [36]. Additionally, HIV infection was associated with higher incidence and reduced clearance of HPV infection [37].

However, the result of this study was different from the study done in Rwanda [38] and several studies conducted in different parts of Ethiopia [9-12,22-26] where there was no association between HIV status and pre-cancerous cervical lesion among women. These discrepancies could be explained in part bydifferences in lifestyle factors such as sociocultural characteristics, nutritional, environmental, sexual behaviour and hygiene of study population. The varying associations may also reflect differences in sample size of the studies.

Finally, this study has some limitations. Among them, firstly, in this study cases and controls were identified only via their current via result; associated with the validity of this screening test, there could be misclassification of cases and controls. This might contribute to underestimating the estimation of cause effect relationship between some of the explanatory variables and the outcome of interest, precancerous cervical lesion. Secondly, despite the fact that, Egger’s test and Begg’s funnel plots detected no evidence of publication bias in the meta-analysis, estimation may not be sufficiently accurate due to small number of included studies.

Conclusion

Cervical cancer continues to be a public health problem in Ethiopia. The finding of this systematic review suggests a positive association between HIV status and pre-cervical cervical lesion.

Therefore regular screening of HIV-infected women is of paramount importance. The success of any strategy is highly dependent on expanding access to all HIV-infected women, obtaining high follow-up rate from the point of screening. Conducting well-designed prospective cohort study to study natural history pre cervical lesion among HIV infected women in Ethiopia is warranted.

Acknowledgement

We would like to express our deepest gratitude to all the primary authors of the included articles. Finally, we would like to acknowledge Ashley Pfister for screeningabstracts and makingthe PRISMAdiagram.

Data Availability Statement

All data relevant to the study are included in the article or uploaded as supplementary information. The data for the meta-analyses conducted are included in the study.

Statement of Ethics

The author has no ethical conflicts to disclose.

Conflicts of Interest

No support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work; no other relationships or activities that could appear to have influenced the submitted work.

Funding Source

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Authors’ Contribution

AAA, KTT and ETT conducted the eligibility screening of shortlisted studies, extracted the data and conducted the analysis with input from all authors. MKT and GAG conducted the initial literature searches. AAA, KTT, ETT GTW and DZB completed the initial drafts of the manuscript. AAA and KTT reviewed the statistical methods. All authors (AAA, KTT, ETT, MKT, GAG, GTW and DZB) read and approved the final manuscript.

References

  1. WHO (2014) Comprehensive cervical cancer control: A guide to essential practice. Second edition. Switzerland.
  2. WHO (2018) Incidence, mortality and prevalence by cancer site, Globocan 876.
  3. Manaf RA, Cecilia NC, SI (2017) Global burden of cervical cancer: A literature review. Int J Public Health 4.
  4. Bruni L, Albero G, Serrano B, Mena M, Gómez D, et al. (2017) ICO/IARC Information centre on HPV and cancer (HPV information centre). Human papillomavirus and related diseases in Ethiopia.
  5. Central Statistical Agency (CSA) [Ethiopia] and ICF (2016) Ababa EA and Rockville, Maryland, USA: CSA and ICF. Ethiopia Demographic and Health Survey: HIV, 47 R.
  6. Delgado JR, Menacho L, Segura ER, Roman F, Cabello R (2017) Cervical cancer screening practices, knowledge of screening and risk, and highly active antiretroviral therapy adherence among women living with human immunodeficiency virus in Lima, Peru. Int. J. STD AIDS 28: 290-293.
  7. Federal democratic republic of Ethiopia ministry of health (2015) Guideline for Cervical Cancer Prevention and Control in Ethiopia.
  8. Teame H, Addissie A, Ayele W, Hirpa S, Gebremariam A, et al. (2018) Factors associated with cervical precancerous lesions among women screened for cervical cancer in Addis Ababa, Ethiopia: A case control study 13: e0191506.
  9. Kassa RT (2018) Risk factors associated with pre-cancerous cervical lesion among women screened at Marie Stops Ethiopia, Adama town , Ethiopia 2017 : A case control study. BMC Res Notes 11: 145.
  10. Alamiraw JA, Asres AW, Adella GA (2020) Predictors of pre-cancerous cervical lesions among women screened for cervical cancer in. Cancer Manag Res 12: 6331-6339.
  11. Getinet M, Gelaw B, Sisay A, Mahmoud EA, Assefa A (2015) Prevalence and predictors of Pap smear cervical epithelial cell abnormality among HIV-positive and negative women attending gynecological examination in cervical cancer screening center at Debre Markos referral hospital , East Gojjam , Northwest Ethiopia. BMC Clin Pathol 15: 1-10.
  12. Nicoletta Colombo, Claire Bramley, Francesca Longo, Jean-Yves Douillard, Svetlana Jezdic AM (2018) Cervical cancer: An ESMO guide for patients. Lugano, Switzerland.
  13. WHO (2013)WHO guidance notes: Comprehensive cervical cancer prevention and control : A healthier future for girls and women. Geneva 27, Switzerland.
  14. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, et al. (2015) Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108.
  15. Federal Democratic Republic of Ethiopia Ministry of Health (2015) National cancer control plan 2016-2020. Ethiopia.
  16. A. Liberati, D. G. Altman, J. Tetzlaff, Mulrow C, Gotzsche PC, et al. (2009) “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration”. The BMJ 339: b2700.
  17. Wells GA, Shea B, and O’Connell D, Peterson J, Welch V (2009) The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses, Ottawa Hospital Research Institute, Ottawa, Canada.
  18. World Health Organization (2013) Guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. World Health Organization
  19. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557.
  20. Dersimonian R, Laird N (1986) “Meta-analysis in clinical trials”, Controlled Clinical Trials 7: 177-188.
  21. Deksissa ZM, Tesfamichael FA, Ferede HA (2015) Prevalence and factors associated with VIA positive result among clients screened at family guidance association of Ethiopia, south west area office, Jimma model clinic, Jimma, Ethiopia 2013 : A cross-sectional study. BMC Res Notes 8: 618.
  22. Misgina KH, Belay HS, Abraha TH (2017) Prevalence of pre-cancerous cervical lesion and associated factors among women in North Ethiopia. J Public Heal Epidemiol 9: 46-50.
  23. Tekalegn Y, Aman R, Woldeyohannes D, Sahiledengle B, Degno S (2020) Determinants of VIA Positivity Among Women Screened for Cervical Precancerous Lesion in Public Hospitals of Oromia Region , Ethiopia : Unmatched Case-Control Study. Int J Womens Health 12: 587-596.
  24. Kote M, Teka T, Kejela G, Getachew T. Magnitude and Factors Associated with Precervical Cancer among Screened Magnitude and Factors Associated with Precervical Cancer among Screened Women in Southern Ethiopia. Adv Public Heal 2019: 8.
  25. Derbie A, Mekonnen D, Mezgebu Y, Biadglegne F (2019) Cervical lesion detection using visual inspection with acetic acid and associated factors among Ethiopian women cervical lesion detection using visual inspection with acetic. Ethiop Med J 2019: 57.
  26. Lidenge SJ (2020) Influence of HIV/AIDS on cervical cancer : A retrospective study from tanzania. J Glob Oncol 3.
  27. Kahesa C, Mwaiselage J, Wabinga HR, Ngoma T, Kalyango JN et al. (2008) Association between invasive cancer of the cervix and HIV-1 infection in tanzania : The need for dual screening. BMC Public Health 8:1-8.
  28. Jolly PE, Mthethwa-hleta S, Padilla LA, Pettis J, Winston S, et al. (2017) Screening, prevalence and risk factors for cervical lesions among HIV positive and HIV negative women in Swaziland. BMC Public Health 17: 1-8.
  29. Michael V (2013) Risk factors for cervical pre cancer lesions among women attending cervical cancer screening. Cancer Manag Res 2013:1-62.
  30. Ntuli ST, Maimela E, Skaal L,Mogale M, Lekota P (2020) Abnormal cervical cytology amongst women infected with human immunodeficiency virus in Limpopo province, South Africa. Afr J Prm Health Care Fam Med 12: a2215.
  31. Temesgen K, Workie TD, MA (2019) Proportions of pre-cancerous cervical lesions and its associated factors among women clients in the age group of 30-49yrs in gynecology ward of dessie referral hospital and fgae, North-East. J Cancer Tumor Int 9: 1-15.
  32. Hailemariam T, Yohannes B, Aschenaki H, Mamaye E, Orkaido G, et al. (2017) Cancer science & therapy prevalence of cervical cancer and associated risk factors among women attending cervical cancer screening and diagnosis center at yirgalem. J Cancer Sci Ther Hailemariam 9: 730-735.
  33. Memiah P, Mbuthia W, Kiiru G, Agbor S, Odhiambo F, et al. Prevalence and risk factors associated with precancerous cervical cancer lesions among HIV-infected women in resource-limited settings prevalence and risk factors associated with precancerous cervical cancer lesions among hiv-infected women in resource-li. AIDS Res Treat. 2012:1-7
  34. Kiviat NB, Sow PS, Gottlieb GS, Ba S, Sy MP (2018) HHS Public Access. Cancer Epidemiol Biomarkers Prev 55: 1-20.
  35. Berek JS (2007) Berek and Novak’s gynecology 14. Stanford: Lippincott Williams Wilkins.
  36. Liu G, Sharma M, Tan N (2019) HIV-positive women have higher risk of HPV infection, precancerous lesions, and cervical cancer: A systematic review and meta-analysis. AIDS 32: 795-808.
  37. Makuza JD, Nsanzimana S, Muhimpundu MA, Pace LE, Ntaganira J, (2015). Prevalence and risk factors for cervical cancer and pre-cancerous lesions in Rwanda. Pan Afr Med J 22.

Citation: Assefa AA, Tegegne KT, Tegegne ET, Tessema MK, Gemeda GA, et al. (2021) HIV Infection and Pre-Cancerous Cervical Lesion among Women in Ethiopia: A Systemic Review and Meta-Analysis. J Oncol Res Treat 6:162. DOI: 10.4172/aot.1000162

Copyright: © 2021 Assefa AA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top